methyl 7-[(5-carbamimidoyl-3-methyl-1H-indole-2-carbonyl)amino]heptanoate | 1026895-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 7-[(5-carbamimidoyl-3-methyl-1H-indole-2-carbonyl)amino]heptanoate
• CAS: 1026895-10-2
• 化学式: C₁₉H₂₆N₄O₃
• 分子量: 358.44
• InChiKey: QOJGMEDCUHMOGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  26
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 7-[(5-carbamimidoyl-3-methyl-1H-indole-2-carbonyl)amino]heptanoate 在 lithium hydroxide 、 potassium carbonate 作用下， 生成 7-{[5-(tert-Butoxycarbonylamino-imino-methyl)-3-methyl-1H-indole-2-carbonyl]-amino}-heptanoic acid
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k
• 作为产物：
  描述：

  3-甲基-4-硝基苯甲腈 在 吡啶 、 4-二甲氨基吡啶 、 lithium hydroxide 、 TEA 、 硫化氢 、 ammonium acetate 、 sodium 、 sodium hydride 、 溶剂黄146 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 锌 、 碘甲烷 作用下， 以 乙醇 为溶剂， 生成 methyl 7-[(5-carbamimidoyl-3-methyl-1H-indole-2-carbonyl)amino]heptanoate
  参考文献：
  名称：

  Use of Conformationally Restricted Benzamidines as Arginine Surrogates in the Design of Platelet GPIIb-IIIa Receptor Antagonists

  摘要：

  The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.

  DOI：

  10.1021/jm970020k